Form 4: Core Labs CEO Awarded Performance Shares Tied to ROIC

Core Laboratories Inc. Chairman and CEO Lawrence Bruno received an award of 204,340 performance shares tied to ROIC and TSR metrics over a three-year period.

Summary

• Lawrence Bruno, Chairman and CEO of Core Laboratories Inc. (CLB), was granted 204,340 performance shares on February 12, 2026.
• The award vests over a three-year performance period, commencing on January 1, 2026, and concluding on December 31, 2028.
• Vesting is contingent on Core Laboratories' Return on Invested Capital (ROIC) performance relative to its Bloomberg Peer Group (BPG).
• 50% of the award will vest if the company achieves the top 35th percentile of ROIC among the BPG, 100% for the top 55th percentile, and 175% for the 85th percentile or above.
• The number of shares vesting will be interpolated on a straight-line basis between these ROIC percentile thresholds.
• Any shares vesting above 100% (up to the maximum of 175%) will be reduced by one-half if the absolute Total Shareholder Return (TSR) for the performance period is negative.
• The award vests on December 31, 2028, even in cases of certain employment terminations, including death, disability, termination by the Company without cause, or retirement by the employee upon reaching 62 years of age.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development for corporate governance, as it strongly aligns the CEO's long-term incentives with key shareholder value metrics like ROIC and TSR, promoting disciplined capital allocation and performance.

Positives

• The performance share award strongly aligns management's incentives with long-term shareholder value creation through specific ROIC and TSR targets.
• The inclusion of Return on Invested Capital (ROIC) as a primary metric encourages efficient capital allocation and sustainable profitability.
• The tiered vesting structure, with a potential payout of up to 175% of the initial grant, provides a significant incentive for exceptional outperformance.
• The award's survival clause for certain employment terminations ensures that the long-term incentive remains in place, promoting continuity of strategic focus.

Negatives

• The award is entirely forward-looking and does not reflect or comment on current financial performance or operational results.
• The maximum potential payout of 175% is subject to a reduction if absolute Total Shareholder Return (TSR) is negative, which could limit upside even with strong ROIC performance.
• The reliance on an externally determined 'Bloomberg Peer Group' for ROIC comparison introduces a variable that the company may not fully control.

Risks

• Achievement of the ROIC percentile and positive TSR vesting targets is uncertain and dependent on future company performance, industry conditions, and market dynamics.
• The Compensation Committee's final determination of ROIC and BPG percentile at the end of the performance period introduces a degree of subjectivity.
• Negative absolute Total Shareholder Return (TSR) could significantly reduce the maximum potential payout, even if ROIC targets are met, impacting executive motivation.

Future Outlook

The filing indicates a clear forward-looking incentive structure for the CEO, aligning his compensation with the company's long-term financial performance, specifically Return on Invested Capital (ROIC) and Total Shareholder Return (TSR), over a three-year period ending December 31, 2028. This suggests a strategic focus on capital efficiency and sustained shareholder returns.

Industry Context

StockSavvy.ai notes that linking executive compensation to Return on Invested Capital (ROIC) and Total Shareholder Return (TSR) is a common and well-regarded practice in the energy services and technology sector. This approach aims to incentivize disciplined capital allocation and long-term shareholder value creation, aligning Core Laboratories with best practices in executive incentive design, similar to its peers who prioritize sustainable returns in a cyclical industry.

Comparison to Industry Standards

• The use of ROIC and TSR as key performance metrics for executive compensation is a widely adopted best practice across various industries, including the oilfield services sector, reflecting a focus on both operational efficiency and shareholder returns.
• Companies such as Schlumberger and Halliburton also incorporate similar long-term incentive plans tied to financial and operational performance, making Core Laboratories' approach consistent with industry leaders.
• The tiered vesting structure (50% at 35th percentile, 100% at 55th, 175% at 85th) provides a strong incentive for outperformance, which is competitive with high-performing companies that aim to reward top-tier results.
• The inclusion of a negative TSR reduction for the maximum payout is a prudent risk mitigation feature, ensuring that executives are not excessively rewarded if overall shareholder value declines, even if internal ROIC targets are met, a practice seen in robust compensation frameworks.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through incentivized long-term value creation, capital efficiency, and improved shareholder returns driven by the CEO's compensation structure.
• Management: Direct impact on the CEO's long-term compensation and incentives, fostering a focus on strategic financial and operational goals.

Next Steps

• Core Laboratories Inc. will continue to operate under the defined performance period from January 1, 2026, to December 31, 2028.
• The Compensation Committee will be responsible for measuring and determining the company's ROIC percentile among the Bloomberg Peer Group and the absolute Total Shareholder Return at the conclusion of the performance period.
• The performance shares will vest, if at all, on December 31, 2028, based on the determined performance against the established metrics.

Key Dates

Recommendation

This Form 4 filing details a standard long-term incentive award for the CEO, aligning his compensation with future performance metrics. While positive for corporate governance and long-term strategy, it does not provide new information on current financial performance or immediate operational changes that would warrant a change in investment stance. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Core Laboratories, CLB, Performance Shares, Executive Compensation, Lawrence Bruno, SEC Form 4, ROIC, Total Shareholder Return, Equity Award, Corporate Governance